| __timestamp | Amneal Pharmaceuticals, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 7890000 |
| Thursday, January 1, 2015 | 109679000 | 14456000 |
| Friday, January 1, 2016 | 118757000 | 19218000 |
| Sunday, January 1, 2017 | 109046000 | 27986000 |
| Monday, January 1, 2018 | 230435000 | 47928000 |
| Tuesday, January 1, 2019 | 289598000 | 96388000 |
| Wednesday, January 1, 2020 | 326727000 | 157743000 |
| Friday, January 1, 2021 | 365504000 | 195293000 |
| Saturday, January 1, 2022 | 399700000 | 237374000 |
| Sunday, January 1, 2023 | 429675000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Amneal Pharmaceuticals, Inc. has consistently outpaced Blueprint Medicines Corporation in SG&A spending. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, peaking at approximately $429 million in 2023. In contrast, Blueprint's expenses grew by a staggering 3,600%, reaching nearly $295 million in the same year.
While Amneal's expenses are higher, their growth rate is more controlled compared to Blueprint's rapid escalation. This suggests that Amneal may have a more stable approach to managing these costs. Investors and stakeholders should consider these trends when evaluating the financial health and operational efficiency of these companies. Understanding how each company allocates resources can provide insights into their strategic priorities and potential for future growth.
GSK plc and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bio-Techne Corporation vs Amneal Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Blueprint Medicines Corporation
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Lantheus Holdings, Inc.
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs Verona Pharma plc
Blueprint Medicines Corporation vs HUTCHMED (China) Limited: SG&A Expense Trends
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs Novavax, Inc.
Amneal Pharmaceuticals, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared